HC Wainwright Reaffirms Buy Rating for Celldex Therapeutics (NASDAQ:CLDX)

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report)'s stock had its "buy" rating reaffirmed by equities researchers at HC Wainwright in a research note issued on Friday,Benzinga reports. They presently have a $80.00 price target on the biopharmaceutical company's stock. HC Wainwright's price objective suggests a potential upside of 300.00% from the stock's previous close. HC Wainwright also issued estimates for Celldex Therapeutics' Q1 2025 earnings at ($0.73) EPS.

Several other research analysts also recently commented on the company. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a research note on Wednesday, January 29th. UBS Group started coverage on shares of Celldex Therapeutics in a research note on Thursday, February 13th. They set a "buy" rating and a $44.00 target price on the stock. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $55.38.

Celldex Therapeutics Price Performance

Shares of NASDAQ:CLDX traded up $0.65 during trading on Friday, hitting $20.00. The company's stock had a trading volume of 737,766 shares, compared to its average volume of 912,710. The company has a 50-day moving average of $23.75 and a 200-day moving average of $28.80. The firm has a market cap of $1.33 billion, a price-to-earnings ratio of -7.78 and a beta of 1.60. Celldex Therapeutics has a 12 month low of $18.61 and a 12 month high of $50.76.

Remove Ads

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.73) by $0.02. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. The firm had revenue of $1.18 million during the quarter, compared to the consensus estimate of $1.25 million. As a group, research analysts anticipate that Celldex Therapeutics will post -2.48 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC grew its holdings in Celldex Therapeutics by 215.7% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company's stock valued at $32,000 after buying an additional 878 shares in the last quarter. KBC Group NV boosted its position in shares of Celldex Therapeutics by 31.2% during the third quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company's stock worth $71,000 after acquiring an additional 495 shares during the last quarter. Headlands Technologies LLC purchased a new position in Celldex Therapeutics during the fourth quarter valued at $81,000. AlphaQuest LLC increased its holdings in Celldex Therapeutics by 171.0% in the 4th quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company's stock valued at $108,000 after acquiring an additional 2,705 shares during the last quarter. Finally, Aquatic Capital Management LLC bought a new stake in Celldex Therapeutics in the 4th quarter valued at $121,000.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.